PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsVerapamil
Verapamil
Verapamil, Verelan (verapamil) is a small molecule pharmaceutical. Verapamil was first approved as Isoptin on 1982-01-01. It is used to treat atrial fibrillation, atrial flutter, hypertension, myocardial infarction, and supraventricular tachycardia amongst others in the USA. The pharmaceutical is active against voltage-dependent L-type calcium channel subunit alpha-1C and voltage-dependent L-type calcium channel subunit alpha-1S. In addition, it is known to target equilibrative nucleoside transporter 4, potassium voltage-gated channel subfamily A member 7, potassium voltage-gated channel subfamily A member 10, sodium leak channel NALCN, voltage-dependent L-type calcium channel subunit alpha-1D, voltage-gated potassium channel KCNC2, cytochrome P450 3A4, voltage-dependent L-type calcium channel subunit alpha-1F, two pore channel protein 1, two pore channel protein 2, and G protein-activated inward rectifier potassium channel 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Verapamil, Verelan (discontinued: Calan, Covera, Isoptin, Verapamil)
Combinations
Trandolapril verapamil (discontinued: Tarka)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Trandolapril
+
Verapamil hydrochloride
Tradename
Company
Number
Date
Products
TARKAAbbVieN-020591 DISCN1996-10-22
4 products, RLD
Hide discontinued
Verapamil hydrochloride
Tradename
Company
Number
Date
Products
VERELANAzurityN-019614 RX1990-05-29
4 products, RLD
VERELAN PMAzurityN-020943 RX1998-11-25
3 products, RLD, RS
VERAPAMIL HYDROCHLORIDEExela Pharma SciencesN-018925 RX1984-03-30
1 products
Show 7 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
amazing faceOTC monograph final2010-05-11
bye bye foundation full coverage moisturizer spf 50C2002632024-12-30
continuous coverage makeupOTC monograph not final2011-12-19
covergirl outlast extreme wear 3-in-1 foundation 24 hr full coverage spf 18 octinoxate sunscreen liquid foundationC2002632024-11-21
dermablend professional cc continuous correction full coverage makeup broad spectrum spf 50 plus sunscreenC2002632023-12-27
dermablend professional smooth camo medium coverage foundation broad spectrum spf 25 sunscreenC2002632023-12-27
dermaquest tm skin therapy, breathable coverage tm mineral foundation spf-30, dermaminerals tmOTC monograph not final2011-02-23
double duty beauty shape tape cloud coverage broad spectrum spf 15 sunscreenC2002632023-12-21
esikaOTC monograph not final2011-09-20
esika perfect skin coverage concealer spf 17OTC monograph final2014-04-08
Show 53 more
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
atrial fibrillationEFO_0000275D001281I48.0
hypertensionEFO_0000537D006973I10
myocardial infarctionEFO_0000612D009203I21
atrial flutterEFO_0003911D001282—
supraventricular tachycardia—D013617I47.1
variant angina pectoris—D000788I20.1
heart failureEFO_0003144D006333I50
diabetic nephropathiesEFO_0000401D003928—
left ventricular dysfunction—D018487—
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C08: Calcium channel blockers
— C08D: Selective calcium channel blockers with direct cardiac effects
— C08DA: Phenylalkylamine derivatives, selective calcium channel blockers with direct cardiac effects
— C08DA01: Verapamil
— C08DA51: Verapamil, combinations
— C09: Agents acting on the renin-angiotensin system
— C09B: Ace inhibitors, combinations
— C09BB: Ace inhibitors and calcium channel blockers
— C09BB10: Trandolapril and verapamil
HCPCS
No data
Clinical
Clinical Trials
184 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———4————4
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameVerapamil
INNverapamil
Description
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile is a tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group. It is a tertiary amino compound, an aromatic ether, a polyether and a nitrile.
Classification
Small molecule
Drug classcoronary vasodilators (verapamil type)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC
Identifiers
PDB—
CAS-ID52-53-9
RxCUI—
ChEMBL IDCHEMBL6966
ChEBI ID77733
PubChem CID2520
DrugBankDB00661
UNII IDCJ0O37KU29 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
KCNC2
KCNC2
Organism
Homo sapiens
Gene name
KCNC2
Gene synonyms
NCBI Gene ID
3747
Protein name
potassium voltage-gated channel subfamily C member 2
Protein synonyms
potassium channel, voltage gated Shaw related subfamily C, member 2, potassium voltage-gated channel, Shaw-related subfamily, member 2, Shaw-like potassium channel, Voltage-gated potassium channel Kv3.2
Uniprot ID
Q96PR1
Mouse ortholog
Kcnc2 (268345)
potassium voltage-gated channel subfamily C member 2 (Q14B80)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Verelan – Elan Corporation
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Verapamil
+
Trandolapril
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Verapamil
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 34,401 documents
View more details
Safety
Black-box Warning
Black-box warning for: Tarka, Trandolapril and verapamil hydrochloride
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
16,943 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use